Labiotech.eu

News and Trends 21 Sep 2022

New Bio Studio program collaboration looks to create life science start-ups

The BioInnovation Institute (BII), has entered a collaboration with Imperial College London in the U.K. to launch a new translational project under its Bio Studio program. The program aims to foster the creation of new life science start-ups based on research to benefit people and society. Based in Denmark, the BII is an international commercial, […]

September 21, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Sep 2022

ten23 health completes superstructure of new sterile production facility

ten23 health, a global contract development and manufacturing organization (CDMO) has completed the superstructure of its new sterile manufacturing facility. The existing facility of ten23 health’s swissfillon AG company in Visp already offers sterile manufacturing of pre-filled syringes, vials, and cartridges for clinical trial and commercial supplies, in collaboration with ten23 health’s development center in […]

September 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 20 Sep 2022

Bioreactor platform launched to support process development for cell and gene therapy

A medical technology company, today announced the launch of a bioreactor platform that supports process development through to commercial manufacturing for the cell and gene therapy (CGT) sector. Terumo Blood and Cell Technologies (Terumo BCT) named its Quantum Flex Cell Expansion System, after identifying the industry’s need for earlier automation to potentially limit additional and […]

September 20, 2022 - 3 minutesmins - By Liza Laws

News and Trends 20 Sep 2022

CytoReason and Pfizer agree deal worth up to $110M for AI drug discovery and development

In a deal with a potential value of $110 million over the next five years, CytoReason has announced an extension of its multi-year partnership with Pfizer. Pfizer will make a $20 million equity investment under the terms of the agreement which will give the company the right to use CytoReason’s artificial intelligence (AI) technology and […]

September 20, 2022 - 3 minutesmins - By Liza Laws

News and Trends 20 Sep 2022

First treatment of rare kidney disease launched in Germany by STADA Arzneimittel

The first and only approved treatment for primary immunoglobin A (IgA) nephropathy, a rare, progressive disease of the kidneys, has been launched in Germany. European commercial partner of Calliditas Therapeutics AB, STADA Arzneimittel AG, says the treatment will launch in additional European countries later. The disease, also known as Berger’s disease, occurs when immunoglobin builds […]

September 20, 2022 - 3 minutesmins - By Liza Laws

News and Trends 20 Sep 2022

Positive results from Arecor Therapeutics’ clinical trial of rapid, concentrated insulin

Arecor Therapeutics today (September 20) announced positive results from a phase 1 clinical trial of its rapid, concentrated insulin product. The company’s candidate named AT278 is formulated using its Arestat technology and designed to significantly accelerate insulin absorption post injection. This is to enable more effective and convenient management of blood glucose levels in people […]

September 20, 2022 - 2 minutesmins - By Liza Laws

News and Trends 20 Sep 2022

GenScript and Avectas look to improve non-viral cell therapy manufacturing

GenScript USA Inc. and Avectas, a cell engineering technology company, are partnering to develop an improved non-viral cell therapy manufacturing process. The two companies said they share a goal of providing their customers with new methods for developing cell therapies with an improved safety profile over viral and non-viral vector techniques. By combining Avectas’ cell […]

September 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 20 Sep 2022

CGT Catapult begins VR training to help ensure future workforce needs

A first-of-its-kind pilot to provide augmented reality (AR) and virtual reality (VR) training to develop the knowledge and skills needed for a career in advanced therapy medicinal product (ATMP) development has been launched. The training will be done by the Cell and Gene Therapy Catapult (CGT Catapult), in partnership with the University of Sheffield Advanced […]

September 20, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Sep 2022

Biopharma company Faron announces escalation data cancer treatment study

A clinical stage biopharma company has announced further dose escalation data from its phase 1/2 study looking at the safety and efficacy of a monotherapy in ten different hard-to-treat cancers. Latest progress from Faron Pharma’s MATINS (Macrophage Antibody To INhibit immune Suppression) study was focused on higher dose levels and frequencies to finalize the dose […]

September 20, 2022 - 4 minutesmins - By Liza Laws

News and Trends 20 Sep 2022

Texture of meat alternatives vastly improved by platform creating alternative active proteins

An Israeli start-up is using technology to clean up labels in products mimicking meat using veggie protein. Meala FoodTech Ltd using a platform to create functionally active proteins designed to replace 1:1 methylcellulose and other hydrocolloids and gums widely used in meat replacements as binding and gelling agents. Meala FoodTech says its multifunctional proteins vastly […]

September 20, 2022 - 4 minutesmins - By Liza Laws

glioblastoma oncolytic virus transgene 2

News and Trends 20 Sep 2022

Collaboration to develop new glioblastoma combination therapy nets €1.06M

Dutch biotech CimCure B.V., French biotech company Covalab, Amsterdam UMC (The Netherlands) and the University of Zurich (Switzerland), have received a €1.06M ($1.08M) grant from EUREKA Eurostars. With a total budget of €2.24M ($2.28M), including investments from the partners, the project aims to develop a new treatment against glioblastoma. CimCure is the lead coordinator of […]

September 20, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 20 Sep 2022

Regen BioPharma files patent on new RNA/DNA-based approach to cancer immunotherapy

Regen BioPharma, Inc. has filed a provisional patent application with the USPTO entitled “Dual Checkpoint Inhibitor Aptamer Based Therapeutics.” The application covers novel compositions of matter capable of acting as conventional checkpoint inhibitor drugs while simultaneously silencing genes that regulate T cells and cancer cells such as NR2F6 and Survivin. The company says this platform […]

September 20, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

New Bio Studio program collaboration looks to create life science start-ups

ten23 health completes superstructure of new sterile production facility

Bioreactor platform launched to support process development for cell and gene therapy

CytoReason and Pfizer agree deal worth up to $110M for AI drug discovery and development

First treatment of rare kidney disease launched in Germany by STADA Arzneimittel

Positive results from Arecor Therapeutics’ clinical trial of rapid, concentrated insulin

GenScript and Avectas look to improve non-viral cell therapy manufacturing

CGT Catapult begins VR training to help ensure future workforce needs

Biopharma company Faron announces escalation data cancer treatment study

Texture of meat alternatives vastly improved by platform creating alternative active proteins

Collaboration to develop new glioblastoma combination therapy nets €1.06M

Regen BioPharma files patent on new RNA/DNA-based approach to cancer immunotherapy

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!